The KEY to the end of chemotherapy in non-small cell lung cancer?

Until recently, advances in the treatment of non-small cell lung cancer (NSCLC) has been with the use of molecular targeted therapy in tumors harboring oncogenic drivers such as epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) or ROS1 gene rearrangement (1-3). However, a majority of non-Asian NSCLC do not harbor an actionable driver oncogene (4) and a platinum doublet with or without bevacizumab is still the standard of care in the first line setting (5).